Overview

Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers

Status:
Active, not recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)

Phase:

Phase 2

Details

Lead Sponsor:

Korea University Guro Hospital

Collaborator:

Korean Cancer Study Group

Treatments:

Neratinib